AstraZeneca (LSE:AZN) Could Be 11% Undervalued Following Q3 Beat And Pipeline Wins
AstraZeneca (LSE:AZN) rose after a packed third quarter. The group beat earnings expectations, reaffirmed 2026 guidance, outlined a cost saving programme and highlighted fresh wins across its oncology and rare disease pipeline.
The latest move fits a clear pattern for AstraZeneca. A 1 day share price return of 6.96% and a 30 day gain of 13.68% have pushed the stock to £139.6. A 1 year total shareholder return of 13.86% and 5 year total shareholder return of 66.42% point to momentum that has been building rather than fading.
Scan how AstraZeneca’s earnings surprise compares with other large-cap healthcare stocks showing strong fundamentals using the list of solid balance sheet and fundamentals (10 results).
AstraZeneca now looks like a high quality engine of drugs and data, and the latest 1 day jump has sharpened the focus. Are investors paying a fair price for that strength, or stretching too far?
Most Popular Narrative: 11% Undervalued
AstraZeneca closed at £139.6, while the most followed narrative points to a fair value of about £157.1. That gap puts the focus squarely on whether the late stage pipeline can justify the difference.
The company's robust and diversified late-stage pipeline, particularly in oncology, rare diseases, and cardiovascular or metabolic therapies, is now underpinned by management's disclosure of 12 programs, each with risk adjusted peak sales potential above US$5b, and several more in the US$3b to US$5b range. This could support high margin revenue growth and earnings as these assets progress from development to launch.
See why 217 investors see AstraZeneca as 11% undervalued.
Result: Fair Value of £157.13 (UNDERVALUED)
Still, AstraZeneca’s story can change quickly if more late stage trials miss key goals or if heavy 2026 capital spending fails to earn attractive returns.
Find out about the key risks to this AstraZeneca narrative.
Next Steps
Mixed feelings on AstraZeneca after this update. Treat that as your cue to move fast: pull up the numbers and stress test the story against your own expectations by weighing its 3 key rewards and 1 important warning sign.
Looking for more ideas beyond AstraZeneca?
If AstraZeneca has sharpened your thinking, you may want to broaden the opportunity set with a few focused stock lists that match clear investing angles.
- Explore resilient compounding potential by scanning companies that screen as high quality and potentially underpriced through the 12 high quality undervalued stocks.
- Find income ideas by reviewing businesses that feature robust payouts in the 5 dividend fortresses.
- Manage portfolio risk by filtering for companies that score well on financial strength using the 5 resilient stocks with low risk scores.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com